Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2021-03-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司董事会关于2020年度证券投资情况的专项说明
Regulatory Filings Classification · 95% confidence The document is a special explanation by the board of directors of Jinling Pharmaceutical Co., Ltd. regarding the company's securities investment situation for the year 2020. It includes detailed financial figures about securities investments, investment income, and internal control measures related to securities investment. The document references quarterly reports and half-year reports where these matters were previously disclosed, indicating it is a supplementary or explanatory note rather than a full financial report. The document length is short (1581 characters) and it is a focused explanation on securities investment, not a full annual or interim report. It does not announce voting results, management changes, or legal proceedings. It is not a certification or a brief announcement of a report publication. Therefore, it fits best under Regulatory Filings (RNS) as a miscellaneous regulatory disclosure that does not fit other specific categories.
2021-03-29 Chinese
金陵药业股份有限公司2020年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the '2020年度监事会工作报告' (2020 Supervisory Board Work Report) of Jinling Pharmaceutical Co., Ltd. It details the supervisory board's activities during 2020, including meetings held, oversight of company operations, financial checks, internal control evaluations, and review of periodic reports such as quarterly and annual reports. The content is a comprehensive report on the supervisory board's work and opinions for the year 2020, including financial oversight and internal control assessments. It is not an announcement or a brief summary but a detailed report on supervisory activities and findings. This fits the category of an Audit Report / Information (AR), as it includes audit opinions, internal control evaluations, and supervisory board oversight, distinct from a full Annual Report (10-K) or other categories. The document length (2780 characters) is relatively short but contains substantive supervisory and audit-related content, not merely an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2020
2021-03-29 Chinese
关于湖州市社会福利中心发展公司业绩承诺实现情况（天衡出具）
Audit Report / Information Classification · 95% confidence The document is an audit report issued by Tianheng Certified Public Accountants (天衡会计师事务所) regarding the performance commitment realization of Huzhou Welfare Center Development Co., Ltd. It includes an auditor's opinion on the management-prepared statement about the achievement of performance commitments related to a cash acquisition of 65% equity. The document references specific audit standards and provides detailed financial data and audit conclusions. It is not a full annual report but a standalone audit report focused on a specific matter (performance commitment realization). The document length is 6188 characters, which is sufficient for a detailed audit report. There is no indication that this is a report publication announcement or a certification letter only. Therefore, the document fits the category of Audit Report / Information (AR). FY 2020
2021-03-29 Chinese
金陵药业股份有限公司关于公司及子公司使用闲置资金购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the company's and its subsidiaries' use of idle funds to purchase low-risk financial products. It details the board meeting approval, investment purpose, amount, risk control measures, and opinions from independent directors and the supervisory board. The document is a formal disclosure about a financing activity related to the use of idle funds for investment in financial products, not a full financial report or earnings release. It is not a report publication announcement or a certification. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage.
2021-03-29 Chinese
金陵药业股份有限公司关于控股子公司业绩承诺实现情况说明的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the performance commitment fulfillment of its controlling subsidiary, Huzhou Social Welfare Center Development Co., Ltd., for the years 2018-2020. It details the original acquisition agreement, the performance targets, audited net profits for each year, the shortfall in meeting the cumulative profit target, reasons for underperformance, and legal actions taken to enforce compensation. The document includes references to audit reports and independent directors' opinions but does not itself contain full financial statements or comprehensive financial performance data. It is a formal disclosure about the status of a performance guarantee and related compensations, which is typical of a regulatory announcement rather than a full financial report or audit report. The document length is 4162 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under Regulatory Filings (RNS), as it is a regulatory announcement about subsidiary performance commitments and related legal and financial matters, not a full annual report, audit report, or earnings release.
2021-03-29 Chinese
金陵药业股份有限公司关于公司2020年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the company's 2020 annual asset impairment provision. It details the amounts and reasons for impairment provisions on various asset categories such as accounts receivable, inventory, fixed assets, biological assets, and goodwill. The announcement includes references to accounting standards, board and supervisory opinions, and audit confirmation by an accounting firm. The document is dated March 26, 2021, and is structured as a formal public disclosure. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a specific announcement about impairment provisions approved by the board and subject to shareholder approval. The length is about 5,647 characters, which is sufficient for a detailed announcement but not a full report. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory announcement about accounting estimates and provisions, not a full audit report or annual report itself.
2021-03-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.